A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 282-289

  Yang, Shih Hung ^a   Lin, Chia Chi ^a,b   Lin, Zhong Zhe ^a,b   Tseng, Yun Long ^c   Hong, Ruey Long ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Taiwan Liposome Company Ltd   (Taiwan)

Author keywords

Cancer; Liposome; Pharmacokinetic; Phase I study; Vinorelbine

Indexed keywords

LIPOSOME; NANOVNB; NAVELBINE; UNCLASSIFIED DRUG;

ACNE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATAXIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLOSSITIS; HUMAN; LEUKOPENIA; LIPOSOMAL DELIVERY; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PLASMA CLEARANCE; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN ULCER; SOLID TUMOR; SYNCOPE; WEIGHT REDUCTION;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; TAIWAN; TREATMENT OUTCOME; VINBLASTINE;

EID: 84856522134     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9522-3     Document Type: Article

References (32)

1. Mangeney P, Andriamialisoa RZ, Lallemand JY, Langlois N, Langlois Y, Potier P (1979) 5'-Noranhydrovinblastine. Prototype of a new class of vinblastine derivatives. Tetrahedron 35:2175-2179 (Pubitemid 10244572)
2. Mangeney P, Andriamialisoa RZ, Langlois N, Langlois Y, Potier P (1979) A new class of antitumor compounds: 5'-nor and 5', 6'- seco derivatives of vinblastine-type alkaloids. J Org Chem 44:3765-3768 (Pubitemid 10169595)
3. Maral R, Bourut C, Chenu E, Mathé G (1981) Experimental in vivo cross-resistance of vinca alkaloid drugs. Cancer Chemother Pharmacol 5:197-199 (Pubitemid 11098959)
4. Maral R, Bourut C, Chenu E, Mathé G (1984) Experimental antitumor activity of 5'-nor-anhydrovinblastine navelbine. Cancer Lett 22:49-54 (Pubitemid 14133157)
5. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC (1991) A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 14:115-119
6. Fumoleau P, Delgado FM, Delozier T et al (1993) Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252 (Pubitemid 23199126)
7. Gebbia V, Testa A, Valenza R et al (1993) A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 29:1358-1359 (Pubitemid 23169918)
8. Conroy T, Etienne PL, Adenis A et al (1996) Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol 14:164-170
9. Bajetta E, Di Leo A, Biganzoli L et al (1996) Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 14:2546-2551 (Pubitemid 26300122)
10. Lacava JA, Leone BA, Machiavelli M et al (1997) Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol 15:604-609 (Pubitemid 27074228)
11. Nasti G, Errante D, Talamini R et al (2000) Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: Results of a phase II study. J Clin Oncol 18:1550-1557 (Pubitemid 30205402)
12. Sharpe M, Easthope SE, Keating GM, Lamb HM (2002) Polyethylene glycol-liposomal doxorubicin: A review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs 62:2089-2126 (Pubitemid 35204042)
13. Drummond DC, Noble CO, Guo Z et al (2009) Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. J Pharmacol Exp Ther 328:321-330
14. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691-743
15. Allen TM (1997) Liposomes. Opportunities in drug delivery. Drugs 54(Suppl 4):8-14 (Pubitemid 27487790)
16. Treat J, Greenspan A, Forst D et al (1990) Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: Phase II study. J Natl Cancer Inst 82:1706-1710
17. Pestalozzi B, Schwendener R, Sauter C (1992) Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Ann Oncol 3:445-449
18. Gelmon KA, Tolcher A, Diab AR et al (1999) Phase I study of liposomal vincristine. J Clin Oncol 17:697-705 (Pubitemid 29075259)
19. Rosenthal DI, Yom SS, Liu L et al (2002) A phase I study of SPI- 077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest New Drugs 20:343-349 (Pubitemid 34823764)
20. Kehrer DF, Bos AM, Verweij J et al (2002) Phase I and pharmacologic study of liposomal lurtotecan, NX 211: Urinary excretion predicts hematologic toxicity. J Clin Oncol 20:1222-1231 (Pubitemid 34177428)
21. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147 (Pubitemid 27337928)
22. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
23. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Dekker, New York
24. Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-160 (Pubitemid 40282557)
25. Khayat D, Rixe O, Brunet R et al (2004) Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. Cancer Chemother Pharmacol 54:193-205 (Pubitemid 39141735)
26. Medical Economics Staff (2003) Physicians' desk reference, 57th ed. Medical Economics
27. Semple SC, Leone R, Wang J et al (2005) Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci 94:1024-1038 (Pubitemid 40780769)
28. Zhigaltsev IV, Maurer N, Akhong QF et al (2005) Liposomeencapsulated vincristine, vinblastine and vinorelbine: A comparative study of drug loading and retention. J Control Release 104:103-111 (Pubitemid 40615239)
29. Webb MS, Johnstone S, Morris TJ et al (2007) In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine. Eur J Pharm Biopharm 65:289-299
30. Liu Y, Lu WL, Guo J et al (2008) A potential target associated with both cancer and cancer stem cells: A combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J Control Release 129:18-25
31. Lotem M, Hubert A, Lyass O et al (2000) Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 136:1475-1480 (Pubitemid 32009267)
32. Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegal T (1997) Long-circulating liposomes for drug delivery in cancer therapy: A review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 24:337-344 (Pubitemid 27112652)